Endpoints News
LightNews LightNews
banner
endpts.com
Endpoints News
@endpts.com
3.1K followers 600 following 1.2K posts
We're where the business of medicine gets answers. An independent news media organization covering biotech, pharma, science, policy, finance, venture capital and markets, and how they drive the life sciences industry. Read us at www.endpts.com.
Posts Replies Media Videos
Pinned
endpts.com
Endpoints News @endpts.com · Dec 17
Just finding us here? Endpoints News has a starter pack with our journalists so you can follow the team!
go.bsky.app/NzDRUhL
endpts.com
Isomorphic Labs says it’s made a major leap in AI drug design, unveiling a new engine it claims outperforms AlphaFold 3 and could unlock new targets and therapies.
Isomorphic claims major advance with new AI drug design engine, in 'step change' versus AlphaFold 3
Isomorphic Labs has revealed an improved AI drug design engine, doubling success rates in protein-drug structure predictions compared to AlphaFold 3, though methodology details remain limited.
endpoints.news
February 10, 2026 at 9:28 PM
endpts.com
Money keeps flowing for private obesity and MASH developers. Cascade is the latest biotech to receive a pool of capital – about $72M.
Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs
Cascade Pharmaceuticals previously disclosed a 140 million yuan round in August 2023 and two 'nearly' 100 million yuan rounds in 2020 and 2022.
endpoints.news
February 10, 2026 at 8:29 PM
endpts.com
Is AstraZeneca on track to meet its $80B revenue target?
Is AstraZeneca on track to meet its $80B revenue target?
AstraZeneca CEO Pascal Soriot aims for $80B annual sales by 2030; company on track with $58.7B in 2025, despite future loss of exclusivity for Brilinta, Soliris, and Farxiga. But it needs to find nine...
endpoints.news
February 10, 2026 at 6:31 PM
endpts.com
What do current biopharma leaders actually think of the regulatory chaos? "It's bat-sh*t crazy."
endpoints.news/bat-sht-craz...
'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos
Q1 Biopharma Sentiment Index shows rising confidence, but hundreds of blunt survey comments reveal concerns about Trump administration, FDA stability, and regulatory uncertainty among industry veteran...
endpoints.news
February 10, 2026 at 4:17 PM
endpts.com
AstraZeneca joins the race for obesity pills with an announcement of promising Phase 2 results for its oral GLP-1.
endpoints.news/astrazenecas...
AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back
AstraZeneca's oral GLP-1 elecoglipron succeeds in Phase 2 obesity and diabetes trials, with Phase 3 starting this year. Drug was licensed from Eccogene for $185M upfront.
endpoints.news
February 10, 2026 at 3:07 PM
endpts.com
Paul McKenzie is stepping down immediately as CEO of CSL, as the company's board becomes "impatient" for a "transformation."
endpoints.news/csls-paul-mc...
CSL’s CEO Paul McKenzie exits after rough few years
The Australian drugmaker's board acknowledged that Paul McKenzie 'didn’t have the skills that we wanted for the future.'
endpoints.news
February 10, 2026 at 2:03 PM
endpts.com
The FDA’s crackdown on drug ads has pharma’s attention, but spending hasn’t dropped much yet. Legal experts say companies are watching closely — without radically changing course so far.
The FDA ad crackdown has pharma's attention. But companies aren't 'radically changing course' — yet
FDA crackdown on misleading drug ads shows little impact as pharma spending remains high. Novartis, Boehringer Ingelheim, and Novo Nordisk continue major ad campaigns.
endpoints.news
February 9, 2026 at 9:34 PM
endpts.com
Takeda and Iambic have signed a $1.7B AI-focused deal to concentrate on small molecules.
Takeda, Iambic sign AI drug discovery deal with up to $1.7B in milestones
Takeda signs AI deal with Iambic worth up to $1.7B, focusing on cancer, GI and inflammation targets. Includes double-digit millions upfront and research payments.
endpoints.news
February 9, 2026 at 8:42 PM
endpts.com
Lilly is buying Orna for $2.4B, the largest buyout of an in vivo cell therapy company to date.
Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition
The total value for Orna Therapeutics would represent the largest buyout of an in vivo cell therapy company to date.
endpoints.news
February 9, 2026 at 6:12 PM
endpts.com
Lilly partners again with Innovent to develop new cancer and immunology drugs.
endpoints.news/lilly-signs-...
Lilly returns to Innovent to partner on cancer and immune diseases
Eli Lilly partners with Innovent Biologics in $350M upfront deal for cancer and immunology drugs, with potential $8.5B in milestones. Innovent to develop through Phase 2 in China.
endpoints.news
February 9, 2026 at 4:01 PM
endpts.com
#ACTRIMS26 Sanofi reveals confluence of factors that led to the failure of late-stage MS trial.
endpoints.news/actrims26-sa...
A confluence of factors contributed to Sanofi's Phase 3 multiple sclerosis trial fail
Sanofi's Phase 3 BTK inhibitor tolebrutinib failed in PPMS trial, showing only 14% reduction in disability progression vs placebo. Lead investigator Robert Fox cited enrollment and baseline issues.
endpoints.news
February 9, 2026 at 2:39 PM
endpts.com
🚨 Novo Nordisk is suing Hims for patent infringement of its semaglutide — in both pill and injectable form. Last week, Hims announced a compounded version of Wegovy pill (Novo's GLP-1) before reversing course on Saturday.
endpoints.news/novo-nordisk...
Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Novo Nordisk sues Hims & Hers for patent infringement over semaglutide products, seeking ban on sales and damages that could reach hundreds of millions of dollars.
endpoints.news
February 9, 2026 at 1:49 PM
endpts.com
Biogen says Leqembi has found steadier footing, with sales climbing as more Alzheimer’s patients stay on the drug into the maintenance phase.
Biogen CEO expects Alzheimer's drug Leqembi to sustain growth
Biogen and Eisai's Alzheimer’s drug Leqembi appears to have reached some stable growth after a bumpy couple of years.
endpoints.news
February 6, 2026 at 9:20 PM
endpts.com
Biotech IPOs are back in force: Agomab and SpyGlass are set to go public, capping the biggest week for biotech listings since 2021, with nearly $1B raised across four debuts.
Agomab, SpyGlass cap biggest week for biotech IPOs since 2021
Four biotech IPOs - Agomab Therapeutics, SpyGlass Pharma, Eikon Therapeutics, and Veradermics - raise $987M total this week, marking biggest biotech IPO week since July 2021.
endpoints.news
February 6, 2026 at 7:09 PM
endpts.com
🎙️Post-Hoc Live today at 12pm ET: The big showdown between drugmakers and compounders is finally here. 🥊 Join @drewsnews.bsky.social and Shelby Livingston as they dissect Hims' decision to sell low-cost GLP-1s. 🥊
endpoints.news/post-hoc-liv...
Live at 12 p.m. ET: The Novo vs. Hims GLP-1 showdown
Live discussion at 12pm ET on Novo Nordisk's legal threat against Hims & Hers over their plan to sell compounded versions of Novo's anti-obesity drug
endpoints.news
February 6, 2026 at 3:55 PM
endpts.com
Illumina reinvents itself and leans into healthcare as it feels the disruptions to NIH funding.
endpoints.news/illumina-bet...
Illumina bets on healthcare customers after NIH funding disruptions
Illumina shifts focus to healthcare market as clinical DNA sequencing grows, while research segment faces challenges from Trump-era NIH funding disruptions.
endpoints.news
February 6, 2026 at 2:55 PM
endpts.com
Priovant Therapeutics heads to Phase 3 trial for its immune skin disease candidate after "landmark, transformative" success in Phase 2.
endpoints.news/roivant-spin...
Roivant spinout heads to Phase 3 with ‘landmark’ data in immune skin disease
Priovant's drug brepocitinib shows success in Phase 2 trial for cutaneous sarcoidosis, reducing disease activity by 21.6 points. Phase 3 trial planned for 2024.
endpoints.news
February 6, 2026 at 2:12 PM
Reposted by Endpoints News
scienceboss.bsky.social
@generatebiomed.bsky.social, one of the biggest companies dedicated to making protein therapies with AI, has filed for an IPO. @andrewedunn.bsky.social and I tackled the S-1 last night and pulled out some interesting details for our story in @endpts.com: endpoints.news/flagships-ge...
Flagship’s Generate files for an IPO in key test for the AI bio field
Generate Biomedicines files for IPO 9 days after starting Phase 3 trial of GB-0895 for severe asthma, with Flagship Pioneering owning 56.6% of AI-focused biotech company.
endpoints.news
February 5, 2026 at 2:28 PM
endpts.com
Bristol Myers is drawing renewed investor interest as a wave of late-stage data readouts approaches, with the company flagging multiple potential approvals and label expansions this year.
Bristol Myers draws pipeline excitement as several data readouts near
Bristol Myers on Thursday flagged at least 10 potential data readouts coming this year that could lead to new approvals or label expansions for existing drugs.
endpoints.news
February 5, 2026 at 9:06 PM
endpts.com
Eikon’s IPO may be the biggest biotech debut in two years, but the sharp valuation reset shows how tough the public markets remain for big-name, big-money biotechs — and what the next wave could face.
What Eikon’s modest IPO says about the future of big-money, big-name biotech
Eikon Therapeutics IPOs at $971M valuation, down nearly 75% from peak, raising $381M despite Nobel Prize science backing and leadership by ex-Merck exec Roger Perlmutter.
endpoints.news
February 5, 2026 at 7:47 PM
endpts.com
Flagship-backed Generate:Biomedicines has filed for an IPO just days after dosing its first Phase 3 patient, setting up a major test for the AI biotech sector.
Flagship’s Generate files for an IPO in key test for the AI bio field
Generate Biomedicines files for IPO 9 days after starting Phase 3 trial of GB-0895 for severe asthma, with Flagship Pioneering owning 56.6% of AI-focused biotech company.
endpoints.news
February 5, 2026 at 7:15 PM
endpts.com
Angitia raised a $130M Series D to advance three clinical-stage biologics for musculoskeletal diseases, continuing momentum for the US-China biotech as it eyes a potential IPO.
Angitia gets $130M Series D for pipeline of musculoskeletal drugs
Angitia Biopharmaceuticals raises $130M Series D for three biologics in musculoskeletal diseases, led by Frazier Life Sciences and Venrock Healthcare Capital Partners.
endpoints.news
February 5, 2026 at 6:22 PM
endpts.com
⚡ Breaking: Hims targets Novo obesity pill with compounded version
Telehealth provider Hims goes after Novo's weight loss pill with compounded version
Hims & Hers to sell $99 compounded version of Novo Nordisk's Wegovy pill, challenging the brand-name drug. CEO Andrew Dudum says move offers more patient choice.
endpoints.news
February 5, 2026 at 3:20 PM
endpts.com
The rare pediatric PRV program is back. A government funding bill reauthorized the FDA’s ability to issue pediatric priority review vouchers through 2029, reviving a key incentive for rare disease drug development.
Rare pediatric PRV program reauthorized until 2029 via government funding law
Trump signs bill reauthorizing FDA's rare pediatric priority review voucher program through 2029, reviving incentive program that expired in 2024.
endpoints.news
February 4, 2026 at 8:56 PM
endpts.com
Veradermics pulled off a $256M upsized IPO for its oral version of Rogaine, a debut that points to renewed investor appetite for biotech listings.
Veradermics lands upsized $256M IPO in sign of demand for oral Rogaine — and biotech listings
Veradermics raised $256M in IPO for oral minoxidil drug VDPHL01, selling 15M shares at $17 each on NYSE. Company testing treatment for pattern hair loss in men and women.
endpoints.news
February 4, 2026 at 8:01 PM